Pre-clinical ADME-Tox service provider, Admescope, has acquired a company specialised in the field of metabolic biotransformation research, MetaSafe AB.
Acquisition
Swedish based company, MetaSafe, is a contract research organisation working with small, midsize and large pharmaceutical companies in the area of drug biotransformation/metabolism. It particularly focuses on clinical phase drug metabolism studies from a safety perspective, but also provides services for the preclinical stage of drug development.
This acquisition will strengthen Admescope’s drug metabolism services further to clinical phase projects, as well as give the benefit of having another high-quality laboratory facility.
“We are excited about the acquisition, and warmly welcoming MetaSafe’s experienced experts as a part of the Admescope team,” said Dr Ari Tolonen, CEO of Admescope. “Due to the excellent synergy between the companies’ service portfolios and operative models, this acquisition will add value for both MetaSafe’s and Admescope’s customers, as together we create a more comprehensive service offering with strengths from the both companies.”
“At MetaSafe we are very pleased to see a future as an integrated part of Admescope,” explained Dr Johanna Haglund, CEO of MetaSafe. “Together we can position our global business even better, more sustainably and more efficiently — to the advantage of our customers and business partners. The merger will create a unique ADME CRO, providing complete ADME services to our customers. MetaSafe’s and Admescope’s services are highly complementary, and in the future we will be in a position to provide our customers with a comprehensive offering from a single source for everything relating to ADME services in order to ensure early and late lead candidate optimisation.”
Admescope, which has its headquarters and laboratories in Oulu, Finland, will continue to operate MetaSafe’s business in Södertälje, Sweden.